ArticleTherapeutics and clinical risk management2021

Italian Real-World Analysis of a Tyrosine Kinase Inhibitor Administration as First- or Second-Line of Therapy in Patients with Chronic Myeloid Leukemia.

Valentina Perrone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.